| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1046882709 |
| P356 | DOI | 10.1186/S13058-015-0658-0 |
| P932 | PMC publication ID | 4672555 |
| P698 | PubMed publication ID | 26643555 |
| P5875 | ResearchGate publication ID | 286402613 |
| P50 | author | Andrea Califano | Q29053203 |
| David Llobet-Navas | Q55729270 | ||
| Wendy A Woodward | Q61037731 | ||
| Daniel Birnbaum | Q64516222 | ||
| P2093 | author name string | Jose Silva | |
| Mary L Alpaugh | |||
| Min Yang | |||
| François Bertucci | |||
| Pascal Finetti | |||
| Jiyang Yu | |||
| Steven N Quayle | |||
| Preeti Putcha | |||
| Ruth Rodriguez-Barrueco | |||
| Veronica Castro | |||
| Patricia Villagrasa | |||
| Laura Saucedo-Cuevas | |||
| Eva Murga-Penas | |||
| P2860 | cites work | ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context | Q21284234 |
| HDAC6 is a microtubule-associated deacetylase | Q24298013 | ||
| Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone | Q24300246 | ||
| The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress | Q24301895 | ||
| Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia | Q24310753 | ||
| Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy | Q24311582 | ||
| A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers | Q24318306 | ||
| HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling | Q24319032 | ||
| Endoplasmic reticulum stress: cell life and death decisions. | Q24536108 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes | Q24647928 | ||
| Signal integration in the endoplasmic reticulum unfolded protein response | Q27860577 | ||
| Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates | Q28114913 | ||
| Proliferation, cell cycle and apoptosis in cancer | Q28189476 | ||
| Cell death: critical control points | Q28240722 | ||
| Comprehensive molecular profiling of lung adenocarcinoma | Q28244995 | ||
| Second-generation shRNA libraries covering the mouse and human genomes | Q28275183 | ||
| Principles of cancer therapy: oncogene and non-oncogene addiction | Q29616779 | ||
| Genetic screens in human cells using the CRISPR-Cas9 system | Q29617411 | ||
| Inflammatory breast cancer: an overview | Q38280412 | ||
| Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy | Q38995507 | ||
| Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells | Q39843809 | ||
| Profiling essential genes in human mammary cells by multiplex RNAi screening | Q40018285 | ||
| Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha | Q40236336 | ||
| A novel human xenograft model of inflammatory breast cancer. | Q41698493 | ||
| Gene expression profiling identifies molecular subtypes of inflammatory breast cancer | Q42475875 | ||
| Molecular determinants of the inflammatory breast cancer phenotype | Q46131097 | ||
| Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A. | Q49131145 | ||
| Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. | Q52564601 | ||
| A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity | Q63383824 | ||
| A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes | Q29618085 | ||
| Reverse engineering of regulatory networks in human B cells | Q30004211 | ||
| Cyfip1 is a putative invasion suppressor in epithelial cancers | Q30490635 | ||
| A resource for large-scale RNA-interference-based screens in mammals. | Q33200135 | ||
| Cancer proliferation gene discovery through functional genomics. | Q33317743 | ||
| The transcriptional network for mesenchymal transformation of brain tumours. | Q33572162 | ||
| Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells | Q33680909 | ||
| Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute | Q33751139 | ||
| High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes | Q33826097 | ||
| Identification of human housekeeping genes and tissue-selective genes by microarray meta-analysis | Q33983496 | ||
| Reverse-engineering human regulatory networks | Q34026195 | ||
| High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing | Q34054107 | ||
| Essential gene profiles in breast, pancreatic, and ovarian cancer cells. | Q34268870 | ||
| Treating breast cancer in the 21st century: emerging biological therapies | Q34326536 | ||
| A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis | Q34398390 | ||
| Pooled shRNA screenings: experimental approach | Q34566186 | ||
| Pooled shRNA screenings: computational analysis. | Q34566191 | ||
| Inflammatory breast cancer (IBC): clues for targeted therapies | Q34754098 | ||
| Functional identification of optimized RNAi triggers using a massively parallel sensor assay | Q35088838 | ||
| Functional viability profiles of breast cancer | Q35281860 | ||
| Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome | Q35576639 | ||
| The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase | Q35774565 | ||
| Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma | Q35915726 | ||
| Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers | Q35952745 | ||
| Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy | Q36559283 | ||
| The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype | Q36778291 | ||
| HDAC6 a new cellular stress surveillance factor. | Q37057578 | ||
| Highly parallel identification of essential genes in cancer cells | Q37068513 | ||
| The medical treatment of inflammatory breast cancer | Q37097315 | ||
| Oxidative stress induces degradation of mitochondrial DNA | Q37181498 | ||
| Rapid creation and quantitative monitoring of high coverage shRNA libraries | Q37440284 | ||
| Mitochondrial stress: a bridge between mitochondrial dysfunction and metabolic diseases? | Q37880356 | ||
| Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma | Q37954600 | ||
| Interplay between HDAC6 and its interacting partners: essential roles in the aggresome-autophagy pathway and neurodegenerative diseases | Q38220520 | ||
| Genomic profiling of inflammatory breast cancer: a review. | Q38226700 | ||
| P2507 | corrigendum / erratum | Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. | Q42361021 |
| P433 | issue | 1 | |
| P304 | page(s) | 149 | |
| P577 | publication date | 2015-12-08 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers | |
| P478 | volume | 17 |
| Q48358070 | ARID1A-mutated ovarian cancers depend on HDAC6 activity |
| Q60920019 | Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis |
| Q42361021 | Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. |
| Q59066462 | Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells |
| Q58768571 | Histone deacetylase 6 in cancer |
| Q89450261 | Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway |
| Q63366138 | Inflammatory breast cancer biology: the tumour microenvironment is key |
| Q39153404 | Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex |
| Q90068431 | Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials |
| Q90526354 | Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways |
| Q89995921 | Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy |
| Q92704418 | Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer |
| Q42361021 | Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. | main subject | P921 |
Search more.